Ampio Pharmaceuticals (AMPE) Trading 4.9% Higher

Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) traded up 4.9% during trading on Wednesday . The stock traded as high as $3.57 and last traded at $3.45. 564,655 shares changed hands during mid-day trading, a decline of 59% from the average session volume of 1,360,631 shares. The stock had previously closed at $3.29.

The company has a market capitalization of $188.97, a PE ratio of -16.45 and a beta of 0.20.

Several large investors have recently made changes to their positions in the company. Wells Fargo & Company MN lifted its position in shares of Ampio Pharmaceuticals by 113.7% during the 4th quarter. Wells Fargo & Company MN now owns 40,671 shares of the specialty pharmaceutical company’s stock valued at $166,000 after buying an additional 21,638 shares in the last quarter. Creative Planning purchased a new position in shares of Ampio Pharmaceuticals during the 4th quarter valued at approximately $116,000. Cypress Capital Management LLC WY lifted its position in shares of Ampio Pharmaceuticals by 50.6% during the 4th quarter. Cypress Capital Management LLC WY now owns 108,400 shares of the specialty pharmaceutical company’s stock valued at $441,000 after buying an additional 36,400 shares in the last quarter. Brandes Investment Partners LP purchased a new position in shares of Ampio Pharmaceuticals during the 4th quarter valued at approximately $204,000. Finally, Carnick & Kubik Group LLC lifted its position in shares of Ampio Pharmaceuticals by 46.2% during the 4th quarter. Carnick & Kubik Group LLC now owns 205,481 shares of the specialty pharmaceutical company’s stock valued at $836,000 after buying an additional 64,914 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2018/02/14/ampio-pharmaceuticals-ampe-trading-4-9-higher.html.

Ampio Pharmaceuticals Company Profile

Ampio Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company’s two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema.

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply